AURA Biopharm AS was founded in 2016 by a team of scientists and drug developers with many years experience in academia and major pharmaceutical companies and a proven track record of success in drug development.

The emphasis of AURA is the development of novel and breakthrough therapies for unmet medical needs and orphan diseases and our slogan “A new opportunity for health” reflects AURA mission to give a new opportunity to diseases in need for new and/or better therapies.

The company operates virtually using a network of external collaborators (consultants, KOLs, CROs, CMOs etc).


Olav Flaten, MD PhD.

Many years in international biotech and pharma industry, with longstanding executive experience from different countries. Excellent network in Scandinavia and other European countries. Member of numerous committees and experienced board member, also of public listed company. High business acumen and knowledge of international business development. Experienced consultant in commercialization, partnering and business development for companies engaged in biotechnology, medical technology, pharmaceuticals and nutraceuticals

Gianni Garotta PhD.

Twelve years research experience in academia at University of Milan, National Cancer Institute of Milan, Wistar Institute of Philadelphia, Basel Institute for Immunology and 35 years of Biotech and Pharma R&D experience at Roche, Human Genome Sciences, Serono and Index venture, Founder of Ganial Immunotherapeutics, RiboVax Biotechnologies, NatiMab Therapeutics and Onconox, CEO of Ganial Immunotherapeutics, RiboVax Biotechnologies and NatiMab Therapeutics

Antonio Guglietta MD, PhD.

Over 25 years experience in science and pharmaceutical industry at organizations located in Italy, US and Spain (U. of Rome, Natl. Inst. Env. Health Sci., GSK, Parke-Davis, Grupo Ferrer). Director of R&D at Grupo Ferrer in Barcelona, Spain from 2000 to 2012. Hands-on experience in drug discovery and development with proven track record of achievements. Several drugs developed all the way to the market and extensive international business experience.

Ferdinando Nicoletti MD.

Full Professor of Pathology and Immunology at the University of Catania (Italy) and CSO of Onconox. More than 250 papers in peer reviewed journals and inventor of 9 patents. Serves in the Editorial Boards of several international journals :Recent Fundraised more than 4 million euros at the University of Catania through national and international research grants. Co-founder of GaNiAl Immunotherapeutic Inc (USA) and Onconox AS (Denmark)


Fabrizio Minoja PhD

Chemistry degree from the University of Milan, Italy. Extensive experience in the preparation, filing and prosecution of international, EP and national patent applications particularly in the area of organic and medicinal chemistry, microbiology, biotechnology and molecular biology, diagnostics and polymer chemistry. European patent attorney and member of several international IP organizations such as the European Patent Institute, the Association Internationale pour la Protection de la Propriété Industrielle and the International federation of Intelectual Property Attorneys.

Klaus Ulrich Berding, MBA,Life Science & Financing Business Advisor.

Over 25 years experience in different roles in Research, Corporate Finance and Consulting. He started his own consulting business LSFA – advising companies on strategic and financial issues with focus on the Life Sciences sector – in January 2003. In March 2005, he joined the Management team of Swiss based BRESLIN AG which specialises in Corporate Finance & Business Development for Pharma, Biotech & MedTech companies. He has been involved in a number of start-up operations and sits on the board of AmypoPharma srl in Italy.